JP2018523689A - ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 - Google Patents

ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 Download PDF

Info

Publication number
JP2018523689A
JP2018523689A JP2018508757A JP2018508757A JP2018523689A JP 2018523689 A JP2018523689 A JP 2018523689A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018523689 A JP2018523689 A JP 2018523689A
Authority
JP
Japan
Prior art keywords
composition
kit
alkyl
agent
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018508757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523689A5 (OSRAM
Inventor
スティーブン ジョセフ シャトルワース，
スティーブン ジョセフ シャトルワース，
アンドリュー デイビッド ホエール，
アンドリュー デイビッド ホエール，
Original Assignee
カルス セラピューティクス リミテッド
カルス セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カルス セラピューティクス リミテッド, カルス セラピューティクス リミテッド filed Critical カルス セラピューティクス リミテッド
Publication of JP2018523689A publication Critical patent/JP2018523689A/ja
Publication of JP2018523689A5 publication Critical patent/JP2018523689A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018508757A 2015-08-19 2016-08-19 ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 Withdrawn JP2018523689A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1514760.6 2015-08-19
GBGB1514760.6A GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use
PCT/GB2016/052575 WO2017029517A1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Publications (2)

Publication Number Publication Date
JP2018523689A true JP2018523689A (ja) 2018-08-23
JP2018523689A5 JP2018523689A5 (OSRAM) 2019-07-25

Family

ID=54258859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018508757A Withdrawn JP2018523689A (ja) 2015-08-19 2016-08-19 ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物

Country Status (22)

Country Link
US (3) US10668077B2 (OSRAM)
EP (1) EP3337477B1 (OSRAM)
JP (1) JP2018523689A (OSRAM)
KR (1) KR20180064387A (OSRAM)
CN (2) CN113786409B (OSRAM)
AU (1) AU2016307885B2 (OSRAM)
CA (1) CA2995898A1 (OSRAM)
DK (1) DK3337477T3 (OSRAM)
ES (1) ES2939815T3 (OSRAM)
FI (1) FI3337477T3 (OSRAM)
GB (1) GB201514760D0 (OSRAM)
HR (1) HRP20230376T1 (OSRAM)
HU (1) HUE061615T2 (OSRAM)
IL (1) IL257499A (OSRAM)
LT (1) LT3337477T (OSRAM)
MX (1) MX2018001926A (OSRAM)
PL (1) PL3337477T3 (OSRAM)
PT (1) PT3337477T (OSRAM)
RS (1) RS64095B1 (OSRAM)
SI (1) SI3337477T1 (OSRAM)
SM (1) SMT202300063T1 (OSRAM)
WO (1) WO2017029517A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020059705A1 (ja) * 2018-09-18 2021-08-30 株式会社ヤクルト本社 キノリンカルボキサミド誘導体を用いるがん併用療法
JP2022537925A (ja) * 2019-07-01 2022-08-31 カルス セラピューティクス リミテッド Ｂ細胞リンパ腫の療法に使用するためのｐｉ３ｋ阻害剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534326T3 (es) 2009-08-20 2015-04-21 Karus Therapeutics Limited Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2020055840A1 (en) * 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20220117966A1 (en) * 2019-02-27 2022-04-21 Astrazeneca Ab Method of treating fibrosis
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
CN114533879B (zh) * 2020-11-19 2023-09-29 广州顺健生物医药科技有限公司 治疗癌症的联合疗法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502404A (ja) * 2009-08-20 2013-01-24 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
BE786081A (fr) * 1971-07-13 1973-01-10 Uniroyal Sa Appareil et procede pour maintenir les tringles des bourrelets de pneu
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN1250294A (zh) * 1999-07-27 2000-04-12 邮电部武汉邮电科学研究院 以太网与同步数字体系或同步光网络融合的适配方法
BR0012863A (pt) 1999-08-03 2002-04-16 Lilly Icos Llc Composições farmacêuticas de "beta"-carbolina
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US8921376B2 (en) 2005-05-20 2014-12-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
WO2008001076A1 (en) 2006-06-26 2008-01-03 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
UA97483C2 (ru) * 2006-08-08 2012-02-27 Чугай Сейяку Кабушики Кайша Производное пиримидина в качестве ингибитора pi3k и его применение
AU2007323836B2 (en) 2006-11-13 2013-04-18 Icos Corporation Thienopyrimidinones for treatment of inflammatory disorders and cancers
CA2672270A1 (en) 2006-12-15 2008-06-26 Gennadi V. Glinksy Treatments of therapy resistant diseases and drug combinations for treating the same
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
WO2008121257A1 (en) 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
JP5658565B2 (ja) * 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
EP2344490A2 (en) 2008-10-03 2011-07-20 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CN101849934B (zh) * 2010-05-25 2011-11-09 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
ME02887B (me) 2011-07-27 2018-04-20 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za tretman raka
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
CN104955824B (zh) 2012-11-20 2017-09-22 豪夫迈·罗氏有限公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物
DK2994465T3 (en) 2013-05-10 2018-10-08 Karus Therapeutics Ltd HISTONDEACETYLASE INHIBITORS UNKNOWN
RU2019134551A (ru) * 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
ES2929576T3 (es) 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502404A (ja) * 2009-08-20 2013-01-24 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020059705A1 (ja) * 2018-09-18 2021-08-30 株式会社ヤクルト本社 キノリンカルボキサミド誘導体を用いるがん併用療法
JP2022537925A (ja) * 2019-07-01 2022-08-31 カルス セラピューティクス リミテッド Ｂ細胞リンパ腫の療法に使用するためのｐｉ３ｋ阻害剤
JP7691939B2 (ja) 2019-07-01 2025-06-12 コンバライフ （シャンハイ） カンパニー リミテッド Ｂ細胞リンパ腫の療法に使用するためのｐｉ３ｋ阻害剤

Also Published As

Publication number Publication date
DK3337477T3 (en) 2023-02-20
US11291669B2 (en) 2022-04-05
US10668077B2 (en) 2020-06-02
GB201514760D0 (en) 2015-09-30
US20210069200A1 (en) 2021-03-11
ES2939815T3 (es) 2023-04-27
CN113786409B (zh) 2024-04-02
HK1251467A1 (en) 2019-02-01
MX2018001926A (es) 2018-06-19
HRP20230376T1 (hr) 2023-06-23
WO2017029517A1 (en) 2017-02-23
SMT202300063T1 (it) 2023-03-17
AU2016307885B2 (en) 2019-07-25
FI3337477T3 (fi) 2023-04-27
KR20180064387A (ko) 2018-06-14
CN108348505A (zh) 2018-07-31
CA2995898A1 (en) 2017-02-23
SI3337477T1 (sl) 2023-04-28
LT3337477T (lt) 2023-03-10
US20180243313A1 (en) 2018-08-30
IL257499A (en) 2018-07-31
HUE061615T2 (hu) 2023-07-28
EP3337477B1 (en) 2023-02-01
RS64095B1 (sr) 2023-04-28
CN113786409A (zh) 2021-12-14
CN108348505B (zh) 2021-10-12
PL3337477T3 (pl) 2023-07-03
PT3337477T (pt) 2023-03-20
EP3337477A1 (en) 2018-06-27
US12257254B2 (en) 2025-03-25
US20230066999A1 (en) 2023-03-02
AU2016307885A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US12257254B2 (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
US11708378B2 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
CN116457358A (zh) 作为ras抑制剂以治疗癌症的吲哚衍生物
US9663487B2 (en) Phosphoinositide 3-kinase inhibitors
US10442815B2 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
JP2018528192A (ja) Ｐｉ３ｋ阻害剤およびｈｄａｃ阻害剤を含む組成物
JP7584802B2 (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト
CA2995902A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
WO2018097162A1 (ja) クマリン骨格を有するスルホンアミド誘導体
EP4536649A1 (en) Quinolone bcl6 bifunctional degraders
HK40065474A (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
HK1251467B (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200601

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200601